Amplia Therapeutics Limited (ATX.AX)
- Previous Close
0.0640 - Open
0.0650 - Bid 0.0610 x 3463500
- Ask 0.0630 x 4114300
- Day's Range
0.0650 - 0.0650 - 52 Week Range
0.0550 - 0.1150 - Volume
9,230 - Avg. Volume
87,838 - Market Cap (intraday)
12.975M - Beta (5Y Monthly) 0.52
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0200 - Earnings Date May 28, 2024 - Jun 3, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Amplia Therapeutics Limited, a pharmaceutical company, focuses on development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. The company's product pipeline includes AMP945, an inhibitor of FAK, for pancreatic cancer and idiopathic pulmonary fibrosis, as well as other solid tumors and fibrotic diseases indications, that has completed Phase I clinical trial; and AMP886 for acute myeloid leukemia (AML) and certain solid tumors.It has a collaboration agreement with the Garvan Institute of Media Research in Sydney. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is headquartered in Melbourne, Australia.
www.ampliatx.comRecent News: ATX.AX
Performance Overview: ATX.AX
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ATX.AX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ATX.AX
Valuation Measures
Market Cap
12.98M
Enterprise Value
9.56M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.88
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-2.23
Financial Highlights
Profitability and Income Statement
Profit Margin
-238.69%
Return on Assets (ttm)
-14.40%
Return on Equity (ttm)
-26.40%
Revenue (ttm)
1.87M
Net Income Avi to Common (ttm)
-4.46M
Diluted EPS (ttm)
-0.0200
Balance Sheet and Cash Flow
Total Cash (mrq)
5.66M
Total Debt/Equity (mrq)
15.18%
Levered Free Cash Flow (ttm)
-4.38M
Company Insights: ATX.AX
ATX.AX does not have Company Insights